Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 424B5

Codexis, Inc.

CDXSNASDAQEQUITYCurrent

SEC Filing

Filed Jul 23, 2026Accepted Jul 23, 2026, 4:41 PM EDTCIK 1200375Accession 0001193125-26-314241
Share

Company context

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® Manufacturing Platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

Current securities

Recent company filings

  1. 10-Q filingAug 11, 2026
  2. Results of Operations and Financial ConditionAug 11, 2026
  3. Other EventsJul 27, 2026
  4. 424B5 filingJul 24, 2026
  5. Results of Operations and Financial Condition · Other EventsJul 23, 2026

As-filed source

Primary evidence